IFNB1 and myeloid sarcoma: The therapy of MS strongly relies on different immunomodulatory and immunosuppressive drugs including beta interferon (IFN-β), which blocks T cell activation, increases interleukin (IL)-10 expression, and maintains blood-brain barrier integrity [12, 13].